Clinical trials: Pioglitazone
Healthy
Study to Assess the Effects of Daily Administration of Pioglitazone on Brain Hemodynamics in Healthy Elderly Participants
The purpose of this study is to assess the effects of pioglitazone, once daily (QD), on brain hemodynamics in healthy elderly participants.
- Trial name
- NCT01456117
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Takeda
Non-alcoholic Fatty Liver Disease
Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)
This study will evaluate changes in liver fat content following multiple oral doses of MK-4074 and Pioglitazone Hydrochloride in adult males and females with fatty liver disease.
- Trial name
- NCT01431521
- Testing
- MK-4074 200 mg, Pioglitazone hydrochloride 30 mg
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer, Endobronchial Dysplasia
Pioglitazone for Lung Cancer Chemoprevention
This is a chemoprevention trial evaluating the diabetic agent pioglitazone. Non-diabetic subjects at risk for lung cancer (based on smoking history, lung function testing, and atypical cells in a sputum sample) receive either…
- Trial name
- NCT00780234
- Testing
- fluorescence bronchoscopy, quantitative high resolution CT scan
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- VA Office of Research and Development
Chronic Hepatitis C
Pioglitazone in Hepatitis C
The presence of insulin resistance (IR) appears to be a key factor in the development of steatosis and disease progression in patience with Hepatitis C virus (HCV) genotype-1 infections similar to levels in Non-alcoholic fatty…
- Trial name
- NCT00189163
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan
Type 2 Diabetes Mellitus
Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"
The purpose of this survey is to determine the onset of new cerebral and cardiovascular events and changes in metabolic syndrome parameters in patients with type 2 diabetes mellitus on long-term pioglitazone (Actos Tablets)…
- Trial name
- NCT02002975
- Testing
- Pioglitazone
- Volunteers
- 18,223 people
- Sponsor
- Takeda
Cirrhosis, Ascites
Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis
The purpose of this study is to investigate the response to pioglitazone on the hepatic venous pressure gradient and peripheral vascular responsiveness to vasoconstrictors in patients with advanced (Child´s Grade B or C)…
- Conditions
- Cirrhosis, Ascites, Portal Hypertension
- Trial name
- NCT00570622
- Testing
- Pioglitazone
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University of Vienna
Diabete Mellitus
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)
This was an open-label, randomized, fed, single-dose, 2-sequence, 2- period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A", "BR3006B,"…
- Trial name
- NCT07083401
- Testing
- Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg, Dapagliflozin 10 mg, Pioglitazone 30 mg
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetes Mellitus, Type 2
Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long-term safety and effectiveness of vildagliptin, an unapproved drug…
- Trial name
- NCT00237237
- Testing
- vildagliptin
- Where
- 2 sites in United States, Germany
- Volunteers
- 588 people
- Sponsor
- Novartis
Calcification of Aortic Valve, Aortic Valve Stenosis
Effects of Pioglitazone in Calcific Aortic Valve Disease
This is a prospective, randomized, comparative, clinical trial conducted by Wuhan Union Hospital that aims to evaluate the efficacy and safety of pioglitazone compared to placebo in patients with calcific aortic valve disease…
- Trial name
- NCT05875675
- Testing
- Drug: Pioglitazone Oral Tablet
- Volunteers
- 100 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Type 2 Diabetes
Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of pioglitazone-azilsartan, once daily (QD), in subjects with type 2 diabetes mellitus with poor glycemic control.
- Trial name
- NCT00376181
- Testing
- Pioglitazone and Azilsartan, Pioglitazone
- Where
- 73 sites in United States, Argentina and 3 more
- Volunteers
- 96 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin
The purpose of this study is to measure microcirculation in type 2 diabetes patients with peripheral edema who are taking pioglitazone, once daily (QD).
- Trial name
- NCT00676260
- Testing
- Pioglitazone
- Where
- United Kingdom
- Volunteers
- 29 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of the combination of vildagliptin, an unapproved…
- Trial name
- NCT00101803
- Testing
- vildagliptin
- Where
- United States
- Volunteers
- 527 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Pioglitazone in Psoriasis- A Clinical and Molecular Study.
The study will assess the effectiveness of Pioglitazone on cellular and clinical levels in terms of improvement of both skin and systemic manifestations of psoriasis.
- Trial name
- NCT01133561
- Testing
- actozone A, actozone B
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Cairo University
Diabetes Mellitus, Type 2
Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)
This is a dose-ranging study that will evaluate the efficacy, safety and tolerability of a range of doses of investigational product and pioglitazone, compared to placebo, administered as monotherapy over 12 weeks in treatment…
- Trial name
- NCT00500331
- Testing
- GSK189075, pioglitazone
- Where
- 136 sites in United States, Argentina and 17 more
- Volunteers
- 334 people
- Sponsor
- GlaxoSmithKline
To Evaluate the Effect of Pioglitazone on Glucose Metabolism of Fat Tissue by Using FDG-PET/CT Imaging
Pioglitazone Decreases Visceral Fat Metabolism
Excess visceral fat is associated with chronic systemic inflammation and cardiovascular complications. Pioglitazone has been reported to variably influence visceral fat volume, but it its effect on metabolic activity of the…
- Trial name
- NCT01819402
- Testing
- Pioglitazone vs Glimepiride
- Where
- Japan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kurume University
Type 2 Diabetes Mellitus
The Practical Evidence of Antidiabetic Combination Therapy in Korea
This study evaluate the efficacy and safety of alogliptin and pioglitazone combination therapy in comparison with either alogliptin or pioglitazone on glucose control in the metformin-treated type 2 diabetic patients in Korea.
- Trial name
- PEAK (NCT02231021)
- Testing
- alogliptin, Pioglitazone, alogliptin + pioglitazone
- Where
- South Korea
- Volunteers
- 216 people
- Sponsor
- Kun-Ho Yoon
Opioid-Related Disorders
Pioglitazone to Treat Opioid Withdrawal Symptoms
Background: Opioid-withdrawal symptoms include runny nose, body aches, chills, sweating, and diarrhea. Many people have these symptoms when trying to stop using opioid drugs.
- Trial name
- NCT01517165
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Endstage Renal Disease, Diabetes
Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients
To test the hypothesis that PPAR-gamma agonist, rosiglitazone, induces carotid plaque regression in diabetic ESRD patients on maintenance PD via its anti-inflammatory property.
- Trial name
- NCT00745914
- Testing
- Pioglitazone
- Where
- 2 sites in Hong Kong
- Volunteers
- 22 people
- Sponsor
- The University of Hong Kong
Type 2 Diabetes
Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients
Primary objective: To evaluate the effect of lixisenatide versus placebo over a period of 24 weeks on glycemic control, as evaluated by glycosylated hemoglobin (HbA1c) reduction, in older type 2 diabetes participants (T2DM) who…
- Trial name
- GetGoal-O (NCT01798706)
- Testing
- Lixisenatide (AVE0010), Antidiabetic background therapy
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 350 people
- Sponsor
- Sanofi
Type II Diabetes
Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of Piemonte association in the treatment of type 2 diabetes mellitus
- Trial name
- PIEMONTE (NCT05028140)
- Testing
- PIEMONTE, EMPAGLIFLOZIN, PIOGLITAZONE
- Where
- Brazil
- Volunteers
- 480 people
- Sponsor
- EMS